Organogenesis Holdings Inc.

NASDAQ:ORGO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.85 +3.21%

+$0.08 today

Market cap
$110.75M
Beta
1.33
P/E (TTM)
-1086.7
EPS (TTM)
-$0.00
52W Low $2.04High $7.08

Volume 0.86M

Average 1.49M

ORGO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Organogenesis Holdings Inc.NASDAQ: ORGO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $3.64M rose 8.0% year over year, behind the +17.6% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 15.9% from the prior quarter. Over 3 fiscal years it compounded at +26.6% a year.

Context

  • Stock-based compensation amounted to 2.4% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +8.0% toward the trailing-twelve-month pace of +17.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.64M-15.9% QoQ
Last fiscal yearDec 2025
$13.3M+25.7% YoY
LTMMar 2026
$13.57M+17.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.0%——
1 year+25.7%——
3-year CAGR+26.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
13.3M USD
Year-over-year change
+25.7%
4-year CAGR
+36.2%

Stock-Based Compensation vs competitors

How ORGO compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +17.6% is the 4th highest of 11, against a peer median of -4.1%.
  • Stock-based compensation amounts to 2.6% of revenue for ORGO, versus a peer median of 3.1%.
ORGO Competitors
Stock-Based Compensation for ORGO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EOLSEvolus, Inc.LTM Mar 2026$19.89M USD-13.9%+24.1%6.6%
EBSEmergent BioSolutions Inc.LTM Mar 2026$16.6M USD+22.1%-28.9%2.5%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$13.57M USD+17.6%+26.6%2.6%
SNDLSNDL Inc.LTM Mar 2026CA$13.13M CAD-20.8%+12.9%1.4%
ANGOAngioDynamics, Inc.LTM Feb 2026$11.69M USD+16.5%-3.0%3.7%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$10.93M USD+20.5%+16.2%—
VREXVarex Imaging CorporationLTM Apr 2026$10.9M USD-28.8%+2.3%1.3%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$9.91M USD-11.7%-13.4%2.4%
MNPRMonopar Therapeutics Inc.LTM Mar 2026$4.07M USD+87.9%+43.4%—
SIGASIGA Technologies, Inc.LTM Mar 2026$3.53M USD+3.6%+27.4%3.8%
BCYCBicycle Therapeutics plcLTM Mar 2026$2.68M USD-107.0%+13.8%4.2%
Peer median (excluding ORGO) —-4.1%+13.3%3.1%

Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income94.9M15.53M4.95M861K37.03M
Depreciation & Amortization16.68M10.73M23.45M17.03M26.94M
Deferred Income Tax(31.98M)1.98M2.01M(10.72M)9.5M
Stock-Based Compensation3.86M6.55M9M10.58M13.3M
Change in Working Capital(39.29M)(34.08M)(18.07M)(48.89M)(132.38M)
Accounts Receivables(30.23M)(8.77M)5.54M(31.8M)(115.8M)
Inventory(9.3M)(9.41M)6.58M(6.2M)(17.92M)
Accounts Payables3.85M3.26M(108K)(2.37M)(528K)
Other Working Capital(3.6M)(19.16M)(30.08M)(8.51M)1.87M
Other Non-Cash Items17.8M24.15M9.59M45.35M35.3M
Operating Cash Flow61.98M24.86M30.92M14.21M(10.31M)
Capital Expenditures(31.22M)(33.9M)(24.36M)(10.03M)(14.15M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(31.22M)(33.9M)(24.36M)(10.03M)(14.15M)
Debt Repayment(2.01M)(3.01M)(5.17M)(67.64M)(1.17M)
Common Stock Issued2.2M000157K
Common Stock Repurchased000(25.48M)0
Dividends Paid000(1.8M)0
Other Financing Activities(1.22M)814K(332K)1.87M(16.35M)
Financing Cash Flow(1.04M)(2.2M)(5.51M)27.64M(17.36M)
Effect of Forex Changes00000
Net Change in Cash29.72M(11.24M)1.05M31.81M(41.82M)
Free Cash Flow30.76M(9.04M)6.55M4.18M(24.46M)

Organogenesis Holdings Inc.

NASDAQ:ORGO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.